Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 1 March 2018, 14:00 HKT/SGT

Source: Singapore eDevelopment Ltd
Singapore eDevelopment (SGX:40V) biomedical subsidiary confirms LB2 efficacy against Ebola

SINGAPORE, Mar 1, 2018 - (ACN Newswire) - Singapore eDevelopment (SGX: 40V) is pleased to announce biomedical subsidiary Global BioLife, Inc. has completed the initial Zaire Ebola research portion for the study of new anti-viral drug LB2, part of its new universal therapeutic drug platform, Linebacker, which is designed to combat a range of diseases, including neurological, anti-microbial, anti-viral, and oncology.

The first documented outbreak of Ebola was in 1976, with more recent notable outbreaks occurring between 2014 - 2016. With fatality rates of up to 90%, Ebola is a severe viral disease transmitted from wild animals to human beings through physical contact, then spreads through human to human contact. There are very few treatment options for Ebola, making infection prevention and infection control practices the strongest defence against the viral disease.

Global BioLife is building on existing research by Mr. Daryl Thompson, the founder of advanced research company GRDG Sciences, LLC. and Director of Scientific Initiatives at Global BioLife, and leveraging on Daryl's expertise in organic and carbohydrate chemistry and use of pandemic technology in research contributing to the development of LB2. The drug displayed efficacy in a much lower dose than T-705 (Favipiravir), the therapeutic agent currently used for treating the Ebola infection.

T-705 (Favipiravir) has been in use since 2014 as an experimental anti-viral drug for treating Ebola. This drug has been shown as effective in decreasing mortality, but must be administered 48 to 72 hours after the Ebola infection has set in. Testing for Global BioLife's anti-viral LB2 was conducted at a highest-rated biosafety level 4 (BSL-4) laboratory in Galveston, Texas. BSL-4 laboratories are used to study life-threatening diseases, employing state-of-the-art systems to protect researchers, staff and the general public from contamination.

Dr. Roscoe Moore, former Assistant Surgeon General of the United States and who serves as the Scientific Advisor to the Linebacker Project, commented, "The results validate our core belief that the Linebacker platform can be a major entry as an effective small molecule anti-infective - effective, and at the same time, with a good safety profile."

In addition to Ebola, the LB2 drug demonstrates similar broad efficacy against SARS, MERS, H5N1 Avian Bird Flu, MRSA, and Cholera. Global BioLife is moving to complete research efforts, and expects positive results from the LB2 drug against ZIKA, Malaria, and the influenza pandemic.

"Based on the Ebola data alone, LB2 is the leading anti-viral drug candidate, with the lowest toxicity. We have high hopes that the LB2 drug has the potential to make real impact in improving people's health globally," said Dr. Peihong (Peggy) Tang, Global BioLife Director and Chief Executive Officer. Dr. Tang has a Ph.D. in Chemical Engineering from Columbia University, and worked for Merck & Co. from 1995-2003 as a Senior Engineer focusing on pharmaceutical process engineering and technical services.

Mr. Chan Heng Fai, Executive Chairman of Singapore eDevelopment, said, "Global BioLife is on the cutting edge of research into real solutions for global health problems."

The Linebacker universal therapeutic drug platform is in final pre-clinical testing against an array of diseases. Global BioLife expects to complete validating laboratory data on the platform, which includes for Alzheimer's and Parkinson's disease, within the next four (4) months. Shareholders and potential investors in Singapore eDevelopment are advised to exercise caution when trading or dealing in Company securities, as there is no certainty or assurance that the transactions mentioned in this announcement will materialise, read any further Company announcements carefully, and consult their stockbrokers, bank managers or solicitors if they have any doubts about the actions they should take.

About Singapore eDevelopment Ltd
Incorporated on 9 Sept 2009 and listed on the SGX in July 2010, Singapore eDevelopment Ltd (SeD) is involved in Property development and investments primarily in the United States and Western Australia; Information technology-related businesses; Development, research, testing, manufacturing, licensing and distribution of biomedical products; and Investment activities. For more information, please visit: or email: [email protected].

About Global BioLife, Inc.
Global BioLife leverages its scientific know-how and intellectual property in providing solutions to problems that have been plaguing the biomedical field for decades. Tapping the scientific expertise of GRDG Sciences and Holista, Global BioLife pledges efforts in R&D and drug discovery and development for the prevention, inhibition and treatment of neurological, oncological and immuno-related diseases.

Global BioLife is also working with partners to develop a DEET alternative second-generation mosquito defense technology, and protection against mosquito transmitted diseases such as Zika and Dengue. Global BioLife is 70% held by Global BioMedical, Inc., a subsidiary of Singapore BioMedical Pte. Ltd., which is wholly-owned by SGX-listed Singapore eDevelopment Ltd. 20% is held by GRDG Sciences, LLC, and 10% by ASX-listed Holista CollTech, Ltd. Please visit

About GRDG Sciences, LLC
Global Research and Discovery Group Sciences, LLC, is an advanced research team formed in Florida by natural product discovery and drug research scientist Daryl Thompson. For more information, please visit

Mar 1, 2018 14:00 HKT/SGT
Topic: Clinical Trial Results
Sectors: BioTech, HealthCare
From the Asia Corporate News Network

Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Singapore eDevelopment Ltd
Jan 28, 2019 12:00 HKT/SGT
Singapore eDevelopment subsidiary Global BioLife's 3F Antimicrobial Fragrance shows Efficacy against Tuberculosis
Nov 7, 2018 19:00 HKT/SGT
Singapore eDevelopment (SGX:40V) Subsidiary, Global BioLife, Proudly Announces Presentation of Parkinson's Research at Neuroscience 2018
June 18, 2018 19:00 HKT/SGT
Singapore eDevelopment Announces Corporate and Business Update
May 31, 2018 18:00 HKT/SGT
Singapore Exchange-Listed Singapore eDevelopment Limited's U.S. Biomedical Subsidiary Global BioLife, Inc. Develops Low Glycemic Modified Sugar
Nov 1, 2017 18:00 HKT/SGT
Singapore eDevelopment's Biomedical Subsidiary Confirms 100% Repellency of 3F Mosquito Fragrance
Oct 24, 2017 18:00 HKT/SGT
SGX-Listed Singapore eDevelopment's Global BioLife Inc Develops Breakthrough Modified Sugar
Aug 15, 2017 19:00 HKT/SGT
Singapore eDevelopment's Global BioLife and U.S.-based Chemia Corporation to Develop Functional Fragrances to Fight Mosquito-Borne Diseases
June 15, 2017 10:15 HKT/SGT
First-Year Performance of Global Systematic Multi-Strategy Fund
May 22, 2017 11:00 HKT/SGT
Singapore eDevelopment Subsidiary Initiates Research on New Universal Drug Platform
More news >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: